The Mome-Air Sava nasal spray is for allergic rhinitis (60 doses)

Dosage form Jar
Specifications Mometason Furoat

Ingredient

Thành phần cho 6ml

Composition information	Content
Mometason Furoat	3mg

Uses

Indications

Mome Air 60 nasal spray indicated in the following cases:

Indications for adults and children 2 years and older to treat symptoms of seasonal allergic rhinitis and allergic rhinitis all year round. Nasal polyps for adults aged 18 and older.

Dynamic pharmacokinetics

Mometason Furoat Monohydrate using nasal spray almost not detected in plasma in pediatric patients and adults despite using sensitive tests with a limited amount of less than 50 PCG/ml.

Before taking The Mome-Air Sava nasal spray is for allergic rhinitis (60 doses)

How to use

After the first bait pump Mome Air nasal spray (10 sprays, until you see the spray evenly), each time the press provides about 100 mg of Mometason Furoat, containing Mometason Furoat Monohydrate is equivalent to 50 microgram Mometason Furoat.

If you do not use a spray for 14 days or more, you must bait pump 2 sprays again, until you see the spray evenly, before using the next time. Shake the jar carefully before each use. The vial should be removed after spraying all the pumps on the label or within 2 months from the first use.

Dosage

Dosage for treatment of seasonal allergic rhinitis and allergic rhinitis all year round

Adults and children aged 12 and older: The usual dose is 2 spray on each side/day (50 micrograms/spray) (total dose of 200 mc).

Children from 2 - 11 years old: The usual recommendation is 1 spray on each side of the nose/day (50 micrograms/spray) (total dose of 100 mcg).

Dosage to reduce nasal congestion is related to seasonal allergic rhinitis

Adults and children aged 12 and older: The usual dose is 2 spray on each side/day (50 micrograms/spray) (total dose of 200 mc).

Children from 2 - 11 years old: The usual recommendation is 1 spray on each side of the nose/day (50 micrograms/spray) (total dose of 100 mcg).

Seasonal dosage prevention of allergic rhinitis

Adults and children 12 years and older: The usual recommendation is 2 spray on each side/day (50 micrograms/spray) (total dose of 200 mc).

In patients with a history of medium -to -severe symptoms of seasonal allergic rhinitis, preventive treatment with Mome - Air can be used up to 4 weeks before the expected starting time of pollen season.

Dosage to treat nasal polyps

Adults aged 18 and older: The usual recommendation of the treatment of nasal polyps is 2 sprays (50 mcg/spray) on each side of the nose daily - 2 times a day (total dose of 400 mcg). 2 sprays (50 mcg/spray) on each side of the nose daily - 1 time (total dose of 200 mc) also effectively in some patients.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose?

In an emergency, call the 115 emergency center immediately or go to the nearest local health station.

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

Unwanted effects (ADR) when using Mome Air 60 that you may encounter.

The adverse reactions related to the treatment of allergic rhinitis are reported in clinical research in adult patients and adults are shown as follows (Table 1).

Table 1: Unwanted effects related to the treatment of allergic rhinitis of Mome - Air

nasal spray

Very common (1/10);

Common (1/100,

Not common (1/1000,

Rare (1/10,000,

Very rare (Common

Nosebleeds, sore throat, nose, nose irritation, nose sores Common

headache The rate of other effects is equivalent to placebo.

In children with unwanted effects such as nosebleeds (6%), headache (3%), nose irritation (2%) and sneezing (2%) are the same as placebo.

In patients with nasal polyps, the rate of other unwanted effects is equivalent to the price and similar in patients with allergic rhinitis treatment.

Unwanted effects related to the treatment of nasal polyps are reported> 1% of patients in clinical research are shown in the following table (Table 2).

Table 2: Unwanted effects related to the treatment of nasal polyps> 1% of Mome Air nasal spray.

Very common (> 1/10); Common (> 1/100, 1/1000, 1/10,000,

(200 mcg 1 time/day)

(200 mcg 2 times/day)

Lower respiratory infections

nosebleeds

Common

Not common

Very common

throat irritation

… Common

Headache

Common

Rarely have instant allergies such as bronchospasm, shortness of breath can occur after spraying Mometason Furoat Monohydrate into the nose. Very rarely have sensitivity and veins are reported. The taste and smell disorder is reported very rare.

When experiencing side effects of the drug, patients need to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Mome Air 60 nasal spray is contraindicated in the following cases:

Hypersensitivity to any ingredients of the drug.

Be cautious when using

Mome Air nasal spray must be used for patients with non -functional respiratory tuberculosis or active, or systemic viruses, bacteria, unac for treatment or herpes simplex in the eye.

After 12 months of treatment with Mome Air nasal spray, there is no evidence of nasal atrophy, the same way, Mometason Furoat tends to restore the nasal mucosa close to the normal model.

As with any long -term treatment, patients who use Mome Air nasal spray for several months or longer must be periodically checked for possible changes in the nasal mucosa.

If the fungal infection appears in the nose or throat, the Mome Air nasal spray is discontinued or may require appropriate treatment. Persistent nose and throat irritation may be an indication to stop the Mome Air nasal spray.

Although Mome Air will control the symptoms of the nose in most patients, simultaneously adding appropriate therapies can reduce other symptoms, especially eye symptoms.

There is no evidence of the hypothalamus of the hypothalamus-HPA (HPA) after prolonged treatment with Mome Air nasal spray. However, patients transferred from long -term use of systemic corticosteroids to Mome Air nasal sprays that need to be carefully monitored.

Corticosteroid cessation of systemic corticosteroids in these patients can lead to adrenal insufficiency for several months until the function of the HPA axis recovers. If these patients show signs and symptoms of adrenal insufficiency, the use of corticosteroids must be repeated and other treatments and appropriate evaluation must be conducted.

While transferring the word corticosteroids to the Mome Air nasal spray, some patients may have symptoms of stopping the use of systemic -acting corticosteroids (for example, joint pain and or muscles, fatigue and begin to depression), despite the reduction of nose symptoms and will need encouragement to continue the treatment of Mome Air nasal spray. Such medication may also be revealing allergens that exists in advance such as allergic conjunctivitis and Eczema, which has been previously inhibited by systemic therapy.

Safety and effectiveness of Mome Air nasal spray has not been studied for use in the treatment of one -sided polyp tumor, polyps related to cystic fibrosis or polyp completely obstructed the nasal cavity.

Polyps are rare or irregular, especially ulcers or bleeding should be considered more carefully.

Patients who use corticosteroids that have been inhibited immunosuppressants must be warned of the risk of exposure to infections (e.g. chickenpox, measles) and the importance of a physician's consultation if there are such contacts.

After using sprayed corticosteroids into the nose, the cases of separate puncture of the nasal septum or increased intraocular pressure have been reported very rare.

Safety and effectiveness of Mome Air nasal spray for nasal polyps in children and teenagers under 18 have not been studied.

The systemic effect of corticosteroids nasal spray is possible, especially at high doses for a long time. Development retardation has been reported in children with corticosteroid treatment for the nasal doses at the allowed dose.

Recommendations for the height of children with long -lasting corticosteroid nasal sprays must be monitored regularly. If the development is slowed down, the therapy should be reviewed with the goal of reducing the corticosteroid dose using the nose, if possible, the lowest dose has the effect of controlling symptoms should be maintained.

Used in pregnant and lactating women

There are no well -controlled or complete studies on pregnant women. After nasal spraying the maximum clinical recommendations for patients, the concentration of mometason in plasma is not measured, so the exposure of the fetus with the drug is thought to be negligible and the ability to be toxicity with reproduction is very low.

Like other corticosteroids for other nose, Mome Air nasal spray should only be used for pregnant women, nursing mothers or women at breeding age when benefits may be greater than the potential risk for mothers, fetuses and young children. Children with mothers use corticosteroids during pregnancy must be carefully monitored about adrenal insufficiency.

The ability to drive and operate machinery

No data.

Interactive drug

Mome air spray has been used simultaneously with loratadin or its main metabolites in plasma. Mometason Furoat concentration in plasma is not detected. Combination treatment is well tolerated.

Storage

Store at a temperature not exceeding 30 ° C, avoiding light.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.